Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2015 Sep 18

PMID 26380158

Citations 14

Authors

C K Yeung

K Yoshida

M Kusama

H Zhang

I Ragueneau-Majlessi

S Argon

L Li

P Chang

C D Le

P Zhao

L Zhang

Y Sugiyama

S-M Huang

Affiliations

Soon will be listed here.

Abstract

The organ impairment and drug-drug interaction (OI-DDI) database is the first rigorously assembled database of pharmacokinetic drug exposure data from publicly available renal and hepatic impairment studies presented together with the maximum change in drug exposure from drug interaction inhibition studies. The database was used to conduct a systematic comparison of the effect of renal/hepatic impairment and pharmacologic inhibition on drug exposure. Additional applications are feasible with the public availability of this database.

Citing Articles

A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions.

Bogaard L, Tsoi K, van de Steeg B, Brandon E, Geers L, van Herwaarden M Front Pharmacol. 2024; 15:1412692.

PMID: 39403136 PMC: 11472019. DOI: 10.3389/fphar.2024.1412692.

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

Huynh C, Dingemanse J, Zu Schwabedissen H, Fonseca M, Sidharta P Clin Transl Sci. 2024; 17(7):e13883.

PMID: 39010703 PMC: 11249824. DOI: 10.1111/cts.13883.

Developing a Knowledge Graph for Pharmacokinetic Natural Product-Drug Interactions.

Taneja S, Callahan T, Paine M, Kane-Gill S, Kilicoglu H, Joachimiak M J Biomed Inform. 2023; 140:104341.

PMID: 36933632 PMC: 10150409. DOI: 10.1016/j.jbi.2023.104341.

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.

Takita H, Scotcher D, Chu X, Yee K, Ogungbenro K, Galetin A Clin Pharmacol Ther. 2022; 112(3):615-626.

PMID: 35652251 PMC: 9540787. DOI: 10.1002/cpt.2672.

Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.

Cottura N, Kinvig H, Granana-Castillo S, Wood A, Siccardi M J Clin Pharmacol. 2022; 62(7):835-846.

PMID: 34990024 PMC: 9304147. DOI: 10.1002/jcph.2025.

References

Johnson T, Boussery K, Rowland-Yeo K, Tucker G, Rostami-Hodjegan A . A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010; 49(3):189-206. DOI: 10.2165/11318160-000000000-00000. View

Feng B, Hurst S, Lu Y, Varma M, Rotter C, El-Kattan A . Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Mol Pharm. 2013; 10(11):4207-15. DOI: 10.1021/mp400295c. View

Ke A, Zamek-Gliszczynski M, Higgins J, Hall S . Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014; 95(5):473-6. DOI: 10.1038/clpt.2014.41. View

Sayama H, Takubo H, Komura H, Kogayu M, Iwaki M . Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J. 2014; 16(5):1018-28. PMC: 4147047. DOI: 10.1208/s12248-014-9626-3. View